Compare

IGF-1 DES vs RU-58841

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
XRedditFacebook

IGF-1 DES

2337 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 51% · Mixed 32% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
48
Appetite control
39
Energy
127
Mood
93
Focus
112

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
144
GI discomfort
118
Dizziness
92
Fatigue
89
Nausea
111

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg

Reports span 0.05–2 mg

0.05–0.1 mg
7
0.1–0.2 mg
15
0.2–0.4 mg
18
0.4–0.6 mg
14
0.6–1 mg
8
1–2 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing21stacking19side effects17igf-1 des20

How repeat users are trending

Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 23 days · Based on 514 repeat reporters

RU-58841

6 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 100% · Mixed 0% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
6
Mood
6

Self-reported dose per injection

Median bucket: 2+ mg · Most common: 2+ mg

Reports span 2 to ≥ 2 mg (open-ended top bucket)

2+ mg
6

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Commonly stacked with

Sources (9)

Published sources linked on the IGF-1 DES and RU-58841 wiki pages.

  1. PubMed

    Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I

    Ballard FJ, Wallace JC, Francis GL, et al. Int J Biochem Cell Biol. 1996

    Source
    Wiki study page →

  2. PubMed

    Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice

    Gillespie C, Read LC, Bagley CJ, et al. J Endocrinol. 1990

    Source
    Wiki study page →

  3. PubMed

    In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness

    Walton PE, Dunshea FR, Ballard FJ. Prog Growth Factor Res. 1995

    Source
    Wiki study page →

  4. PubMed

    IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys

    Tomas FM, Walton PE, Dunshea FR, et al. J Endocrinol. 1997

    Source
    Wiki study page →

  5. PubMed

    Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats

    Read LC, Tomas FM, Howarth GS, et al. J Endocrinol. 1992

    Source
    Wiki study page →

  6. ClinicalTrials.gov

    des(1-3)IGF-1 / IGF-1 DES studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →

  7. PubMed

    RU 58841, a new specific topical antiandrogen: a candidate for the treatment of androgenetic alopecia

    Miyamoto H, Yeh S, Lardy H, et al. J Steroid Biochem Mol Biol. 1997

    Source
    Wiki study page →

  8. PubMed

    Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques

    Pan HJ, Wilding G, Uno H, et al. Endocrine. 1998

    Source
    Wiki study page →

  9. PubMed

    Effects of topical antiandrogen and 5-alpha-reductase inhibitors on sebaceous glands in male fuzzy rats

    Ye F, Imamura K, Imanishi N, et al. Skin pharmacology : the official journal of the Skin Pharmacology Society. 1997

    Source
    Wiki study page →

Explore other peptides